Carisma Therapeutics Revenue and Competitors

Location

#2159

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Carisma Therapeutics's estimated annual revenue is currently $28.1M per year.(i)
  • Carisma Therapeutics's estimated revenue per employee is $407,156
  • Carisma Therapeutics's total funding is $121M.

Employee Data

  • Carisma Therapeutics has 69 Employees.(i)
  • Carisma Therapeutics grew their employee count by -46% last year.

Carisma Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Interim VP FinanceReveal Email/Phone
5
VP, Scientific OperationsReveal Email/Phone
6
VP, Discovery and Translational ScienceReveal Email/Phone
7
VP, Program and Portfolio ManagementReveal Email/Phone
8
VP, Clinical DevelopmentReveal Email/Phone
9
SVP Human ResourcesReveal Email/Phone
10
General Counsel and Corporate SecretaryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
N/A7627%N/AN/A
#4
$0.9M6-14%N/AN/A
#5
$1.1M70%N/AN/A
#6
$10.9M703%N/AN/A
#7
$0.7M929%N/AN/A
#8
$4M26-16%N/AN/A
#9
$1.7M1122%N/AN/A
#10
$7.6M492%N/AN/A
Add Company

What Is Carisma Therapeutics?

Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.

keywords:N/A

$121M

Total Funding

69

Number of Employees

$28.1M

Revenue (est)

-46%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Carisma Therapeutics News

2022-04-06 - Carisma Therapeutics to Present Engineered Cell Therapy ...

Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting ... (PRNewsfoto/...

2022-03-22 - Novartis signs initial agreement with Carisma Therapeutics for ...

Carisma (www.carismatx.com ) is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform...

2021-04-09 - CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

PHILADELPHIA, April 9, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) ...

2021-03-18 - CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

PHILADELPHIA, March 18, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pennsylvania (Penn) and focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in the Phas ...

2021-03-01 - CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

PHILADELPHIA, March 1, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 millio ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M698%N/A
#2
$14.1M691%N/A
#3
$10.8M6917%$37M
#4
N/A691%N/A
#5
$3.5M698%N/A